Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma

(2013) L. Zheng et al.   CLINICAL CANCER RESEARCH

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy

(2012) Byung Woog Kang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hyperpolarized 13C Spectroscopy Detects Early Changes in Tumor Vasculature and Metabolism after VEGF Neutralization

(2012) S. E. Bohndiek et al.   CANCER RESEARCH

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

AMPK: a nutrient and energy sensor that maintains energy homeostasis

(2012) D. Grahame Hardie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival

(2011) W. N. William et al.   ANNALS OF ONCOLOGY

Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization

(2011) G. Nardo et al.   CANCER RESEARCH

Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials?

(2011) Piotr Potemski   JOURNAL OF CLINICAL ONCOLOGY

Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

(2011) Timothy J. Price et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

(2010) D. Tsavachidou-Fenner et al.   ANNALS OF ONCOLOGY

Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer

(2010) Y Baba et al.   BRITISH JOURNAL OF CANCER

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

(2010) Adrian M Jubb et al.   LANCET ONCOLOGY

AMP-activated protein kinase and cancer

(2009) W. Wang et al.   Acta Physiologica

Histological evaluation of AMPK signalling in primary breast cancer

(2009) Sirwan M Hadad et al.   BMC CANCER

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

(2009) J. M. L. Ebos et al.   CLINICAL CANCER RESEARCH

Anticancer strategies involving the vasculature

(2009) Victoria L. Heath et al.   Nature Reviews Clinical Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY